Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 20/20 | 0.72 |
| ▸ | ACACA | Q13085 | 6/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620134 | 1.00 | ACACB (0.72) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619805 | 0.84 | ACACB (0.70) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619812 | 0.84 | ACACB (0.70) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619864 | 0.84 | ACACB (1.00) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619861 | 0.84 | ACACB (1.00) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619743 | 0.84 | ACACB (0.69) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL1619741 | 0.84 | ACACB (0.69) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050685 | 0.82 | ACACB (0.66) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050686 | 0.81 | ACACB (1.00) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL5423741 | 0.79 | ACACB (0.61) | ACACBACACACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928243-B2 | e.g. N-{(2Z)-3-[4-(4-isopropoxyphenoxy)phenyl]-1-methylprop-2-enyl}acetamide; antidiabetic agent; type II diabetes, atherosclerosis and cardiovascular diseases | ABBOTT LABORATORIES (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CYP2C9 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.